Back to Agenda
Session 6: Signal Detection
Session Chair(s)
Bruce Valliant
Head of Pharmacovigilance and Medical Information
Pharmascience Inc., Canada
Methods selected for detection of safety signals for a drug are dependent upon the safety profile of the drugs. The safety profile will also have a direct impact on how many reports of adverse drug reactions would be received over a given time period. The expectedness, quantity, seriousness and severity of such reports will all impact on the methods to be used in the signal detection process. As well, the capacity of a small pharmaceutical company to undertake a robust signal detection process may be somewhat limited as compared with that of a large multi-national corporation. Presentations will consider the effectiveness of various methodologies based on these scenarios and compare that with expectations of the regulatory authorities.
Learning Objective : At the conclusion of this session, participants should be able to:- Better understand the selection of signal detection methodolies
- Have better insights of what methods would meet the needs for a given drug
- Have a better understanding of exectations and considerations of the health authorities in the signal detection process
Speaker(s)
Health Canada Perspective on Selection of Signal Detection Process
Stéphane Bérard, MS
Health Canada, Canada
Regional Regulatory Compliance and Enforcement Specialist
Speaker
Bruce Gordon, MSc
Health Canada, Canada
Senior Evaluator
Industry Considerations, Limitations Affecting Choices for Signal Detection
Ruben Ayzin Rosoky, MD, PhD
Novartis, France
Global Program Safety Lead
Panel Discussion
All Session Speakers, United States
Have an account?